Condition: Rectal Cancer · Sponsor: Hebei Medical University Fourth Hospital
This single-arm trial will explore the efficacy and safety of long-course neoadjuvant chemoradiation with liposomal irinotecan and capecitabine guided by UGT1A1 status in patients with locally advanced rectal cancer.
This description comes directly from the study's public registry record.
Linlin Xiao, Ms. · 18533167355 · drxiaolinlin@163.com
Always discuss trial participation with your own doctor first.
| Hebei Medical University Fourth Hospital | Shijiazhuang, Hebei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06210971